Introduction
Chronic hepatitis caused by persistent hepatitis C virus (HCV) infection may lead to the development of liver cirrhosis (LC) and eventually to the complication of hepatocellular carcinoma (HCC).
1 LC has been recognized as one of the major risk factors of HCC and hepatic failure in patients with persistent HCV infection. To prevent the development of HCC and the progression to hepatic failure in HCV-related LC (LC-C), it is important to keep serum aminotransferase levels as low as possible. 2 Interferon therapy has diverse benefi cial effects for HCV-related chronic liver diseases: promoting HCV elimination, suppressing HCV replication, ameliorating the activity of hepatitis, and eventually preventing the progression of hepatic fi brosis and the occurrence of HCC. However, its use is sometimes limited in elderly patients and in patients with marked thrombocytopenia, diabetes, severe systemic arteriosclerosis, or psychological disease, because of the increased risk of harmful or irreversible adverse effects (e.g., cerebral hemorrhage, depression). Therefore, the establishment of alternative strategies is required for such LC-C patients.
Iron reduction therapy (IRT) was fi rst introduced by Hayashi et al., 3 based on the histochemical detection of iron deposits in the liver, and then on the detection of lysosomal iron stores in hepatocytes. Hepatic iron accumulation induces enhanced generation of reactive oxygen species (ROS), thus damaging hepatocytes. 4, 5 Recently, a randomized controlled study of Japanese chronic hepatitis C patients showed that biweekly phlebotomy for 3 months signifi cantly reduced serum alanine aminotransferase (ALT) levels. 6 It has been reported that in HCV-infected patients, intrahepatic iron accumulation and the resultant ROS production enhances as hepatic fi brosis progresses, 7 suggesting that IRT might be useful for LC-C patients. However, for Background. Iron reduction therapy (IRT) has been recognized as benefi cial for chronic hepatitis C patients. However, its effi cacy for hepatitis C virus-related liver cirrhosis (LC-C) has not been elucidated. We evaluated the effi cacy and safety of IRT for LC-C patients. Methods. Twenty-two LC-C patients were treated with biweekly phlebotomy and low iron diet for 6 months, in addition to regular hepatoprotective therapy. Nineteen sex-and age-matched patients who refused to receive IRT were used as controls. The effi cacy of IRT was evaluated on the basis of biochemical parameters. Results. Of 22 patients receiving IRT, 19 completed the 6-month treatment. IRT signifi cantly reduced serum levels of aspartate aminotransferase (from 89 to 57 U/L; P = 0.003), alanine aminotransferase (from 101 to 54 U/ L; P < 0.001), and α-fetoprotein (from 28 to 12 ng/mL; P = 0.003). These changes were not observed in the controls. Two patients whose serum albumin concentrations were less than 3.6 g/dL at the beginning of IRT withdrew from IRT because of the new appearance of ascites. Conclusions. IRT improved the serum levels of aminotransferases and α-fetoprotein in LC-C patients and was generally safe; however, IRT should be performed in patients who maintain serum albumin concentrations of more than 3.6 g/dL.
patients with compensated LC-C, the effi cacy and safety of IRT, that is, the combination of phlebotomy and a low-iron diet, has not been previously elucidated. Therefore, we planned this pilot study to evaluate it.
Materials and methods

Patients
From October 2003 to March 2005, 22 LC-C patients (10 men and 12 women, 66 ± 11 years old) entered this pilot study after informed consent was obtained. All patients were positive for serum HCV-RNA and had abnormal serum ALT levels. Serum aspartate aminotransferase (AST) and ALT levels of less than 35 U/L were defi ned as the normal ranges. Basically, the diagnosis of LC was made according to the histological fi ndings of percutaneous liver biopsy, and was confi rmed by imaging fi ndings (e.g., liver surface irregularity, swelling of the left and caudal lobes, presence of splenomegaly, and development of esophageal or gastric varices) and by laboratory data such as platelet counts of less than 10.0 × 10 4 /µL 8 and serum hyaluronic acid levels of more than 237 ng/mL. 9 All 22 patients had splenomegaly, and seven of these had esophageal varices. Twenty of these patients had platelet counts of less than 10.0 × 10 4 /µL, and 18 had serum hyaluronic acid levels of more than 237 ng/mL. Three of the 22 patients refused liver biopsy, so the diagnosis of LC was made using imaging fi ndings and a formula for estimating liver cirrhosis proposed by Ikeda et al. 8 Its accuracy for diagnosing LC was as high as 91.2%. The exclusion criteria at entry were (1) previous interferon therapy within 6 months; (2) decompensated LC (Child-Pugh classifi cation B or C); (3) hemoglobin values of less than 12 g/dL; (4) serum albumin concentrations of less than 3.3 g/dL; (5) severe complications such as cardiac, pulmonary, renal, or hematological disease; and (6) pregnancy. All patients underwent hepatoprotective therapy such as ursodeoxycholic acid or glycyrrhizin injection for more than 6 months before entry. Of the 22 patients, eight had been administered oral branched-chain amino acids for more than 6 months before entry. None had received regular administration of oral diuretics or albumin infusion. These therapies were not changed after this study was begun.
When informed consent was requested of the LC-C patients, some of them refused to participate in this study. Of these, 19 age-and sex-matched patients were selected and used as controls for the comparison of biochemical markers. These patients continued only hepatoprotective therapy for 6 months or more.
When IRT was begun, the body mass index (BMI) was calculated. Patients were considered to have hypertension if their systolic/diastolic pressure was greater than 140/90 mmHg, or if they were taking antihypertensive drugs. Patients were considered to have diabetes if they had a fasting glucose level equal to or higher than 126 mg/dL, or if they were taking insulin or oral hypoglycemic drugs.
Histological examination
Percutaneous ultrasonography-guided liver biopsy was performed before entry into the study, and the liver specimens were fi xed in 10% formalin and stained using hematoxylin-eosin and the Azan-Mallory methods. The presence of hepatic steatosis was defi ned as macrovesicular fat accumulation in more than 30% of the hepatocytes affected.
IRT
IRT consisted of a periodic phlebotomy and a low-iron diet. Removal of 200 mL of blood from female patients with body weight of less than 60 kg or of 400 mL from other patients was repeated biweekly. Phlebotomy was planned to be continued for 6 months, but was discontinued according to the following criteria: (1) hemoglobin values of less than 10 g/dL, (2) serum ferritin levels of less than 10 ng/mL, (3) the appearance of adverse effects, or (4) patient's refusal to continue phlebotomy. In addition, all patients in the IRT group were advised to reduce their iron-rich food intake during the treatment and were instructed by a registered dietitian. To aid with compliance, each patient was given a comprehensive list of iron-rich foods that they were to avoid, as well as instructions on how to complete dietary records, which required a listing of all food and drink consumed over a 3-day period once every 3 months throughout the treatment. All patients in the IRT group were instructed to reduce their consumption of beans, shellfi sh, green vegetables, meat, and seaweed and replace them with refi ned carbohydrates. Dietary energy (30 kcal/kg of body weight/day), nutritional balance, and iron intake (6 mg/day) during the IRT were assessed based on the dietary records by using the nutrition analysis software BASIC-4 for Windows version 2.0 (Kagawa Nutrition University Publishing Division, Tokyo, Japan).
Laboratory tests
Complete blood counts, including hemoglobin values and platelet counts, and biochemical parameters such as serum AST, ALT, albumin, bilirubin, α-fetoprotein (AFP), hyaluronic acid, and ferritin levels were measured monthly using standard automated analyzers. The amounts of serum HCV-RNA were measured by the Amplicor monitoring method (Roche Diagnostic System, Basel, Switzerland). In the IRT group, blood was drawn for tests just before phlebotomy was performed.
Ethics
This study was carried out in accordance with the World Medical Association Helsinki Declaration, and was approved by the ethics committee of Showa Inan General Hospital. All patients gave their informed consent to participate in the study.
Statistics
Statistical analyses were performed using SPSS software 11.0J for Windows (SPSS, Chicago, Illinois, USA). Qualitative variables were expressed as percentages and compared using the χ-squared test. Quantitative data were expressed as means and standard deviations and were compared using the unpaired or paired twotailed t test. A probability value of less than 0.05 was considered to be statistically signifi cant.
Results
Effects of IRT on laboratory tests
Of the 22 patients receiving IRT, 19 completed the 6-month treatment. There were no differences in the patients' backgrounds between the IRT and the control groups (Table 1) . Serum AST and ALT levels in the IRT group were signifi cantly decreased after the treatment (from 89 ± 33 to 57 ± 19 U/L; P = 0.003, and from 101 ± 44 to 54 ± 24 U/L; P < 0.001, respectively) ( Figs.  1 and 2 ), but remained unchanged in the control group (from 84 ± 26 to 82 ± 23 U/L, and from 93 ± 26 to 91 ± 27 U/L, respectively) (Fig. 2) . Serum AFP levels in the IRT group were also signifi cantly decreased after the treatment (from 28 ± 20 to 12 ± 6 ng/mL; P = 0.003), but were constant in the control group (from 32 ± 24 to 31 ± 24 ng/mL) (Fig. 2) . As a result of the IRT, the hemoglobin values and serum ferritin levels were decreased (from 14.5 ± 1.1 to 11.7 ± 1.9 g/dL; P < 0.001, and from 237 ± 145 to 26 ± 21 ng/mL; P < 0.001, respectively) (Fig.  2) . The platelet counts were signifi cantly increased after the IRT (from 9.2 ± 2.9 to 11.7 ± 2.5 × 10 4 /µL; P = 0.003) (Fig. 2) . Serum albumin, bilirubin, and hyaluronic acid levels remained unchanged after the treatment (Fig. 2) .
Clinical parameters after 6 months of IRT
Several clinical parameters after 6 months of IRT were compared with those of the controls. Serum AST and ALT levels were signifi cantly lower in the IRT group than in the control group (57 ± 19 vs. 82 ± 23 U/L; P = 0.001, and 54 ± 24 vs. 91 ± 27 U/L; P = 0.003, respectively) (Fig. 2) . Serum AFP levels were also lower in the IRT group than in the control group after 6 months (12 ± 6 vs. 31 ± 24 ng/mL; P = 0.042) (Fig. 2) . The hemoglobin values and serum ferritin levels signifi cantly dropped in the IRT group compared with those in the control group (11.7 ± 1.9 vs. 13.8 ± 1.1 g/dL; P < 0.001, and 26 ± Quantitative data were expressed as means ± SD. P values were calculated using the unpaired two-tailed t test or the χ-squared test IRT, iron reduction therapy; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, α-fetoprotein, HCV-RNA; circulating hepatitis C virus RNA 21 vs. 223 ± 111 ng/mL; P < 0.001, respectively) (Fig. 2) . The platelet counts were higher in the IRT group than in the controls (11.7 ± 2.5 vs. 8.4 ± 3.7 × 10 4 /µL; P = 0.004) (Fig. 2) . On the other hand, serum albumin, bilirubin, and hyaluronic acid levels did not differ between the two groups after 6 months (Fig. 2) .
Association between improvement of clinical parameters and iron reduction
To examine whether iron reduction contributed to the improvement of serum aminotransferase levels in this study, the patients receiving IRT were divided into two groups according to their serum ferritin levels as measured after 6 months of treatment (more or less than 10 ng/mL), and the changes in their clinical parameters were compared. As shown in Table 2 , six patients reached serum ferritin levels of less than 10 ng/mL after 6 months of IRT. Serum AST, ALT, and AFP levels after the treatment were similar in the two groups, but the change in AST levels was signifi cantly greater in patients with serum ferritin levels of less than 10 ng/mL than in patients with serum ferritin levels of more than 10 ng/mL ( Table 2 ). The changes in ALT and AFP levels tended to be greater in patients with serum ferritin levels of less than 10 ng/mL (Table 2) .
Adverse effects
IRT was generally tolerated in LC-C patients. However, three of 22 LC-C patients withdrew from IRT. One patient refused phlebotomy because of the pain experienced at the venous puncture. The remaining two patients showed a new appearance of ascites due to decreased serum albumin levels. One of these patients was a 41-year-old obese man suffering from diabetes, and the other was a 70-year-old woman with hypertension. The serum albumin levels of these patients at the beginning of IRT were 3.5 and 3.4 g/dL, respectively. Discontinuance of phlebotomy and addi- tional oral administration of spironolactone resulted in the rapid disappearance of the ascites. Albumin infusion was not performed. In the control group, neither the new appearance of ascites nor HCC was observed.
Discussion
This pilot study demonstrated that IRT signifi cantly improved the serum levels of aminotransferases and AFP for patients with LC-C. Moreover, IRT can be performed safely in patients with compensated LC-C. As far as we know, this is the fi rst study concerning the effi cacy and safety of IRT for LC-C patients.
The remarkable characteristic of this study is that only compensated LC patients were allocated. Histological diagnosis of LC only by ultrasonography-guided liver biopsy sometimes leads to misinterpretation because of a high sampling error. 8, 10 In this study, the diagnosis of LC was made fundamentally according to the histological fi ndings, and was confi rmed by imaging and laboratory fi ndings. Thus, the diagnosis of LC is considered to be valid in this study.
Six months of IRT signifi cantly decreased serum aminotransferase levels, which may have been caused by reduced iron-induced hepatotoxicity. As shown in Table 2, the effi cacy of iron reduction is supported by the fact that the degree of improvement of serum AST levels was greater in patients with serum ferritin levels of less than 10 ng/mL than in those who showed with levels of more than 10 ng/mL after the treatment. The probability that the improvement in serum aminotransferase levels resulted from other hepatoprotective therapies such as ursodeoxycholic acid or glycyrrhizin injection is considered to be very low, because the dose of these hepatoprotective agents was unchanged during this study and because these agents were also administered to the control group, in which the serum aminotransferase levels did not change.
Another notable fi nding in this study is that IRT signifi cantly reduced serum AFP levels. Until now, only low-dose long-term interferon injection therapy has been recognized to improve serum AFP levels.
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Since a high level of AFP is suggested to be one of the major risk factors for the development of HCC, 12, 13 lowering the serum AFP levels is important to prevent HCV-related hepatocarcinogenesis. Hepatic iron accumulation induces mitochondrial abnormalities and enhanced ROS generation, 14 causing the formation of 8-hydroxy-2′-deoxyguanosine (8-OHdG) 14, 15 and p53 mutation, 16 which may eventually lead to the initial step toward HCC. It has also been reported that hepatic iron accumulation disrupts the balance between hepatocyte proliferation and apoptosis in transgenic mice expressing HCV polyprotein 14 and in patients with chronic hepatitis C. 17 Furthermore, an in vitro study using mouse hepatocytes revealed that iron overload promoted Cyclin D1 expression and accelerated hepatocyte division. 18 In fact, it has been demonstrated that IRT signifi cantly lowered hepatic 8-OHdG levels and reduced the incidence rate of HCC in patients with chronic hepatitis C. 19 Therefore, maintaining hepatic iron contents as low as possible by long-term IRT might be useful for preventing HCV-related hepatocarcinogenesis, especially for patients with LC-C. Verifying this requires long-term follow-up observations.
There is a possibility that IRT, especially periodic phlebotomy, can decrease serum albumin concentrations. It has been unclear whether IRT is indicated for patients with compensated cirrhosis and serum albumin levels of less than 3.7 g/dL. This study demonstrated for the fi rst time that, even in compensated cirrhosis, regu- Table 2 . Comparison between IRT group patients with serum ferritin concentrations more and less than 10 ng/mL after 6 months of treatment Ferritin < 10 (n = 6) Ferritin > 10 (n = 13) P Quantitative data were expressed as means ± SD. P values were calculated using the unpaired two-tailed t test. AST, aspartate aminotransferase; ALT, alanine aminotransferase; AFP, α-fetoprotein lar repeated phlebotomy is risky for patients with serum albumin levels of less than 3.6 g/dL. Therefore, in such patients, adjustment of phlebotomy (e.g., reduction of removed blood volume, extension of the interval between phlebotomies) is needed. It is evident that a low-iron diet plays an important role in ameliorating the effect of IRT. 20 Many compensated LC-C patients have subclinical protein energy malnutrition (PEM); 21, 22 excessive dietary iron restriction would worsen it. Careful nutritional evaluation and appropriate pharmacological interventions to improve PEM, such as regular branched-chain amino acid supplementation and a late-evening snack before starting IRT, and repeated education by dietitians, are essential if patients are to complete IRT safely and effi ciently.
Long-term interferon therapy has been demonstrated to reduce development of HCC and improve survival of LC-C patients. 23 However, interferon therapy is not perfect as it has unpleasant adverse effects such as fever and appetite loss and is expensive. In addition, interferon therapy is risky for elderly patients and for patients with severe thrombocytopenia or depression. On the other hand, IRT has few adverse effects and is not so expensive; IRT can be performed safely in patients with cirrhosis with thrombocytopenia or psychological diseases. Thus, we think that IRT might compensate for the imperfections of interferon therapy in LC-C patients.
Concerning IRT for LC-C patients, there are some points to be evaluated hereafter. First, to confi rm these benefi cial effects of IRT, large-scale long-term prospective studies of compensated LC-C patients are needed. Second, since iron deposition enhances collagen synthesis in hepatic stellate cells and promotes the progression of hepatic fi brosis, 24 it would be of great value to evaluate whether long-term IRT can cause regression of hepatic fi brosis in patients with LC-C. Finally, the establishment of safe iron reduction strategies for LC-C patients having serum albumin levels of less than 3.6 g/dL, for example, the development of a new method of phlebotomy that removes only erythrocytes and transfuses the remainder into the vein, would be benefi cial.
In conclusion, we demonstrated that IRT signifi cantly reduced serum aminotransferases and AFP levels in LC-C patients. IRT was generally safe; however, IRT should be performed in patients with serum albumin concentrations of more than 3.6 g/dL.
